Osteoprotegerin (OPG) Recombinant Protein | OPG recombinant protein

Recombinant Human Osteoprotegerin, His (OPG Human)

Cat. Num. AAA555525

• Gene Names: TNFRSF11B; OPG; TR1; OCIF; PDB5
• Reactivity: Human
• Applications: Western Blot
• Purity: Greater than 80.0% as determined by:; (a)Analysis by RP-HPLC.; (b)Analysis by SDS-Page.
• Synonyms: Osteoprotegerin (OPG); Recombinant Human Osteoprotegerin; His (OPG Human); OPG recombinant protein

• Host: E.Coli
• Reactivity: Human
• Purity/Purification: Greater than 80.0% as determined by:; (a)Analysis by RP-HPLC.; (b)Analysis by SDS-Page.
• Form/Format: The protein was lyophilized from concentrated (1mg/ml) solution with 1X PBS, 0.1% SDS and 1mM DTT.
• Sequence Length: 401

• Applicable Applications for OPG recombinant protein: Western Blot, Antibody production, Protein assay
• Reconstitution: It is recommended to reconstitute the lyophilized Osteoprotegerin in sterile water not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
• Preparation and Storage: Lyophilized Osteoprotegerin although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Osteoprotegerin should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Related Product Information for OPG recombinant protein

Recombinant Human OCIF produced E.coli cells is a single, non-glycosylated, polypeptide chain containing amino acids 201-401 and having a molecular mass of 31 kDa which includes 4 kDa His tag. The OPG is purified by chromatographic techniques.

Product Categories/Family for OPG recombinant protein

Proteins; Growth/Differentiation Factors and Small Molecules; Bone Morphogenetic Proteins (BMPs) /Growth Factors; OPG

References

1. Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease. Thromb Haemost 2007 May;97(5):868-702. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007 Jun;49(6):1392-83. The sex-specific association of serum osteoprotegerin and receptor activator of nu clear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007 May;156(5):555-624. Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. Eur J Endocrinol 2007 May;156(5):539-455. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.Acta Oncol 2007;46(2):221-96. Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. Eur J Oral Sci 2007 Apr;115(2):131-6

NCBI and Uniprot Product Information

• NCBI GI #: 2072185
• NCBI GeneID: 4982
• NCBI Official Full Name: osteoprotegerin
• NCBI Official Synonym Full Names: tumor necrosis factor receptor superfamily member 11b
• NCBI Official Symbol: TNFRSF11B
• NCBI Official Synonym Symbols: OPG; TR1; OCIF; PDB5
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 11B
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 11B
• UniProt Gene Name: TNFRSF11B
• UniProt Synonym Gene Names: OCIF; OPG
• UniProt Entry Name: TR11B_HUMAN

NCBI Description

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

Uniprot Description

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Inhibitor; Secreted, signal peptide; Secreted

Chromosomal Location of Human Ortholog: 8q24

Cellular Component: proteinaceous extracellular matrix; extracellular space; extracellular region

Molecular Function: cytokine activity; receptor activity

Biological Process: response to drug; response to magnesium ion; extracellular matrix organization and biogenesis; apoptosis; response to estrogen stimulus; negative regulation of odontogenesis of dentine-containing teeth; response to arsenic; negative regulation of bone resorption; signal transduction; skeletal development; response to nutrient

Disease: Paget Disease, Juvenile